Championing regulatory efficiency
There’s tremendous value in regulatory efficiency.
So we’ve taken a leadership role in advising the FDA in their effort to create new, more efficient regulatory pathways
for biosimilar drug development and approval. The more we can do to advocate for a more cost-efficient approach
for the process, the more sustainable the future for biosimilars.